Acceleron

Merck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH study
Fierce Pharma
Mon, 11/25/24 - 09:52 am
Merck
Acceleron
Winrevair
sotatercept
PAH
clinical trials
Merck scores key FDA approval for pulmonary arterial hypertension drug Winrevair
Fierce Pharma
Wed, 03/27/24 - 11:22 am
Merck
FDA
PAH
Winrevair
sotatercept
Acceleron
Sotatercept- the breakthrough PAH has been waiting for?
Clinical Trials Arena
Thu, 11/10/22 - 10:31 am
Merck
sotatercept
Acceleron
PAH
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Fierce Biotech
Mon, 10/10/22 - 11:06 am
Merck
Acceleron
clinical trials
sotatercept
PAH
pulmonary arterial hypertension
Merck cuts 170 jobs at Acceleron right on heels of $11.5B buyout
Fierce Pharma
Wed, 03/30/22 - 11:05 am
Merck
Acceleron
M&A
layoffs
Cambridge
The top 10 biopharma M&A deals in 2021
Fierce Pharma
Tue, 01/18/22 - 10:53 am
M&A
CSL
Vifor
Jazz Pharmaeuticals
GW Pharma
Novo Nordisk
Dicerna
Horizon Therapeutics
Viela Bio
Perrigo
HRA Pharma
Sanofi
Kadmon
Merck
Acceleron
Pfizer
Arena Pharmaceuticals
Translate Bio
Trillium Therapeutics
Amgen
Five Prime Therapeutics
Is Merck's Planned Acquisition of Acceleron in Trouble?
Motley Fool
Sat, 11/13/21 - 09:55 pm
Merck
Acceleron
M&A
Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout
Fierce Pharma
Sun, 10/24/21 - 10:40 pm
Bristol Myers Squibb
Acceleron
M&A
Aurinia Pharmaceuticals
Bristol Myers pledges to sell its Acceleron shares as activist investors circle Merck's $11.5B buyout — report
Endpoints
Thu, 10/21/21 - 09:31 am
Merck
Acceleron
M&A
Bristol Myers Squibb
Report: Multiple Suitors - Including BMS - Vied for Acceleron’s Attention
BioSpace
Thu, 10/14/21 - 11:12 pm
Merck
Acceleron
M&A
Bristol Myers Squibb
Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180
Fierce Pharma
Tue, 10/12/21 - 11:35 pm
Merck
Pharma CEOs
Robert Davis
M&A
Acceleron
Is an Acquisition of Acceleron a Smart Move for Merck?
Motley Fool
Fri, 10/8/21 - 10:35 am
Merck
M&A
Acceleron
PAH
Keytruda
Biopharma needs a biggie to avoid a down deal year
EP Vantage
Thu, 10/7/21 - 11:07 am
M&A
Merck
Acceleron
Sanofi
Translate Bio
Amgen
Teneobio
Pfizer
Trillium
Perrigo
HRA Pharma
Trouble builds for Merck's $11.5B Acceleron buy as activist investor behind Gilead's Immunomedics deal says too early, too cheap
Fierce Pharma
Fri, 10/1/21 - 10:55 am
Merck
Acceleron
M&A
investors
Avoro Capital
Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug
BioSpace
Thu, 09/30/21 - 12:01 am
Merck
Acceleron
M&A
PAH
Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report
Endpoints
Tue, 09/28/21 - 12:15 am
Merck
Acceleron
M&A
PAH
sotatercept
Rumor mill says Acceleron is speeding towards $11bn sale
Pharmaforum
Sun, 09/26/21 - 11:28 pm
Acceleron
M&A
Acceleron, under threat of fines, reports out a negative study
RAPS.org
Wed, 05/26/21 - 12:00 am
Acceleron
clinical trials
regulatory
Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign
Endpoints
Wed, 05/19/21 - 10:42 am
Acceleron
sotatercept
PAH
The "Rare Disease Company Coalition" Launches to Share the Unique Challenges and Promise of Rare Disease Therapy Development to Support Continued Progress and Patient Access
Yahoo/Businesswire
Thu, 05/13/21 - 12:04 pm
Rare Diseases
Rare Disease Company Coalition
drug development
drug discovery
Acceleron
Aeglea BioTherapeutics
Agios Pharmaceuticals
Alnylam
Harmony Biosciences
Orchard Therapeutics
Orphazyme
Sarepta Therapeutics
Taysha Gene Therapies
Ultragenyx

Pages